ZUMANDIMINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZUMANDIMINE (ZUMANDIMINE).
ZUMANDIMINE is a selective norepinephrine reuptake inhibitor that increases synaptic norepinephrine levels, enhancing adrenergic signaling in the CNS and peripheral nervous system.
| Metabolism | Primarily metabolized by CYP2D6 to its active metabolite, desmethylzumandimine; minor pathways involve CYP3A4. |
| Excretion | Renal excretion accounts for 65% of elimination (primarily as unchanged drug via glomerular filtration and tubular secretion), biliary/fecal excretion accounts for 30% (with enterohepatic recycling of metabolites), and 5% is metabolized via CYP3A4 with subsequent excretion. The cumulative urinary recovery of unchanged drug is 60-70% within 48 hours. |
| Half-life | Terminal elimination half-life is 12-15 hours in healthy adults (range 10-18 hours). In moderate renal impairment (CrCl 30-50 mL/min), half-life prolongs to 20-28 hours; in severe hepatic impairment (Child-Pugh C), half-life extends to 24-35 hours. This supports twice-daily dosing in normal renal function and requires dose adjustment in renal or hepatic impairment. |
| Protein binding | Highly bound (92-95%) primarily to albumin (80%) and alpha-1-acid glycoprotein (15%). Free fraction increases in hypoalbuminemia (e.g., cirrhosis, nephrotic syndrome), potentially enhancing pharmacodynamic effects. |
| Volume of Distribution | Volume of distribution is 0.8-1.2 L/kg (total Vd), indicating extensive tissue distribution. Mean Vd is 50-70 L in a 70 kg adult, suggesting binding to peripheral tissues and sequestration in erythrocytes (blood-to-plasma ratio 0.9). |
| Bioavailability | Oral bioavailability is 75-85% (with minimal first-pass metabolism). Subcutaneous bioavailability is 80% (relative to IV). Intravenous bioavailability is 100%. Food increases absorption (Cmax increased by 15-20%, AUC unchanged). |
| Onset of Action | Intravenous: 5-10 minutes (peak plasma concentration at end of infusion); Oral: 1-2 hours (median time to therapeutic effect, with clinical response noted within 2-4 hours after first dose); Subcutaneous: 30-45 minutes (bioavailability 80% versus IV). |
| Duration of Action | Duration of clinical effect is 12-24 hours depending on dose and route. At standard doses (e.g., 50 mg IV), effect duration is 12-16 hours; extended-release oral formulation provides 24-hour coverage. Tachyphylaxis may occur with continuous use beyond 7 days. |
| Molecular Weight | 378.46 |
The typical adult dose of ZUMANDIMINE is 250 mg intravenously every 12 hours infused over 60 minutes.
| Dosage form | TABLET |
| Renal impairment | For GFR 30-89 mL/min: no adjustment. For GFR 15-29 mL/min: 250 mg every 24 hours. For GFR <15 mL/min or on hemodialysis: 250 mg every 48 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 125 mg every 12 hours. Child-Pugh Class C: not recommended. |
| Pediatric use | For children ≥2 years: 5 mg/kg (max 250 mg) intravenously every 12 hours. For children <2 years: not established. |
| Geriatric use | Start at lower end of dosing range (250 mg every 12 hours) due to age-related renal function decline. Monitor renal function and adjust per renal dosing guidelines. |
| 1st trimester | Teratogenic in animal studies; avoid use unless no alternative. |
| 2nd trimester | Associated with fetal growth restriction; monitor fetal growth. |
| 3rd trimester | May cause neonatal jaundice and kernicterus; avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for ZUMANDIMINE (ZUMANDIMINE).
| Placental transfer | Crosses placenta; fetal plasma levels up to 50% of maternal levels. |
| Breastfeeding | Excreted in breast milk; use caution due to potential for serious adverse reactions in nursing infants. |
| Lactation Rating | L4 |
■ FDA Black Box Warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS - ZUMANDIMINE increases the risk of suicidal thoughts and behaviors in children, adolescents, and young adults. Close monitoring is required during initial treatment.
| Serious Effects |
Hypersensitivity to zumandimineSevere hepatic impairmentHistory of drug-induced agranulocytosis
| Precautions | Risk of serotonin syndrome when used with other serotonergic drugs. May cause hypertension and tachycardia; monitor blood pressure and heart rate. Potential for activation of mania/hypomania in patients with bipolar disorder. Avoid abrupt discontinuation to prevent withdrawal symptoms. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase zumandimine exposure. A high-fat meal delays absorption (Tmax increased by ~1.5 h) and reduces peak concentration by approx 20%; therefore, take on an empty stomach if a rapid onset is desired. No other significant food interactions reported. |
Loading safety data…
| Teratogenic Risk | Data limited. First trimester: Possible increased risk of neural tube defects and cardiac malformations based on animal studies (doses 2x MRHD). Second and third trimester: Risk of fetal growth restriction and oligohydramnios due to potential uteroplacental hypoperfusion. Avoid use if alternative therapy available. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function (serum creatinine, electrolytes), and fetal growth via serial ultrasound every 3-4 weeks starting at 20 weeks. Perform fetal echocardiography if exposed in first trimester. Monitor for oligohydramnios if used after 20 weeks. |
| Fertility Effects | In animal studies, high doses (5x MRHD) caused decreased implantation rates and increased preimplantation loss. Human data absent. May impair fertility in females by altering ovarian function; males: no data. |
| Clinical Pearls | Zumandimine is a dual orexin receptor antagonist (DORA) indicated for insomnia. It has a rapid onset of action (Tmax ~1-2 h) and a half-life of approximately 8 h. Avoid co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole) as they increase AUC by 2-3 fold. Use with caution in patients with COPD or sleep apnea due to potential respiratory depression. Avoid alcohol, as it exacerbates CNS depression. Hepatic impairment (Child-Pugh B/C) reduces clearance; no dose adjustment needed for mild impairment but avoid in severe impairment. Abrupt discontinuation may cause rebound insomnia, so taper if used long-term. |
| Patient Advice | Take zumandimine only when you are ready for a full night's sleep (at least 7-8 hours) and do not take it if you will not have that time available. · Do not drive or operate machinery the morning after taking zumandimine, as it may cause drowsiness. · Avoid alcohol while taking zumandimine; it can increase side effects like dizziness and drowsiness. · Do not take zumandimine with grapefruit juice, as it may increase drug levels and risk of adverse effects. · Tell your doctor if you have liver problems, lung disease, or a history of sleepwalking or complex sleep behaviors. |